| Palo Alto Veterans Institute for Research | Irene Lorenzo Llorente | Inhibitory interneurons derived from human induced pluripotent stem cells to treat stroke |
$2,140,122 |
| Novoglia, Inc. | Dr. Sunil Gandhi Ph.D | Gene-corrected human microglia for the treatment of adult onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) |
$1,417,948 |
| University of California, San Francisco | Faranak Fattahi | Drug discovery for gastrointestinal motility disorders using hPSC-derived enteric ganglioids |
$1,954,367 |
| University of Southern California | Dr. Justin K Ichida | Development of a VAV2 antisense oligonucleotide (ASO) treatment for ALS |
$2,072,560 |
| Cedars-Sinai Medical Center | Dr. Ritchie Ho | C9orf72 repeat expansion-tuned allelic suppression by CRISPRi as an ALS therapy |
$2,274,768 |
| University of California, Davis | Ricardo Anibal Maselli MD | Treatment of Myasthenic Syndrome due to Choline Acetyltransferase Deficiency Using AAV9-mediated Gene Therapy |
$1,500,000 |
| Adverum Biotechnologies | Cameron Keast Baker | Development of an Optogenetic Vision Restoration Gene Therapy Using an Engineered Form of Melanopsin |
$1,150,820 |
| Stanford University | Dr. Robert Negrin MD | Orthogonal IL2 Receptor Transduced Regulatory T Cells for Clinical Application |
$1,920,652 |
| University of California, San Francisco | Michael Wilson | A First-in-Class Treatment for Progressive Multifocal Leukoencephalopathy Via Multimodal Immune System Engineering |
$2,182,396 |
| Stanford University | Dr. Michael F Clarke | Developing a breast cancer stem cell drug |
$2,053,727 |
| Cedars-Sinai Medical Center | Dr. Ke Liao | RNA-based therapeutics to augment regulatory T cells: a novel approach to treat myocarditis |
$2,264,509 |
| University of Southern California | Dr Linda Sher | Assessing the Functional, Immunologic and Microbiologic Characteristics of Human Livers Created in Chimeric Pigs |
$2,736,590 |
| City of Hope, Beckman Research Institute | Dr Jianhua Yu | Reprogramming Somatic Cells into iPSCs Engineered with an Anti-PSCA CAR to Develop Allogeneic Off-the-Shelf Cell Therapy to Treat Pancreatic Cancer |
$2,263,500 |
| Vertuis Bio, Inc. | Lukas Bachmann | Expanded Capacity AAV Retinal Gene Therapy Enabled by Efficient RNA-Joining Technology |
$0 |
| Gladstone Institutes, J. David | Lyandysha (Lana) Viktorovna Zholudeva | Excitatory spinal interneurons from human pluripotent stem cells to treat spinal cord injury |
$2,942,198 |
| University of California, Los Angeles | Prof. Song Li | Vax-CT to promote formation of cancer-specific T memory stem cell for personalized cancer immunotherapy |
$2,267,714 |
| University of California, Los Angeles | Dr. Richard Joseph Pietras | Reversal of dysregulated myelopoiesis in breast cancers and cancer stem cells to boost antitumor immunotherapy |
$2,327,680 |
| Greenstone Biosciences, Inc. | Paul D Pang | Drug Discovery for Duchenne Muscular Dystrophy Using Patient-Derived Human iPSCs |
$675,000 |
| University of California, Berkeley | Mr. Fyodor Urnov | A Treatment for Artemis-deficient Severe Combined Immunodeficiency using Non-Viral CRISPR-driven Safe Harbor Transgenesis in Hematopoietic Stem Cells |
$1,809,372 |
| University of California, Davis | Aijun Wang PhD | In Utero Treatment of Duchenne Muscular Dystrophy with Non-viral Gene Editing |
$2,035,544 |
| Rubedo Life Sciences Inc. | Marco Quarta | Pharmacological regenerative treatment of idiopathic pulmonary fibrosis targeting the senescent niche of lung progenitor cells. |
$1,450,876 |
| University of California, Los Angeles | Dr. Gerald Lipshutz | Gene Therapy for SLC6A8 Creatine Transporter Disorder |
$2,296,920 |
| University of California, Los Angeles | Frank Pajonk | Development of novel small molecules against cancer stem cells in solid cancers |
$2,340,000 |
| Scripps Health | Dr. Darryl D. D’Lima | Pluripotent Stem Cells for Tendon Tissue Engineering |
$2,734,163 |
| Cedars-Sinai Medical Center | Dmitriy Sheyn | Microgel encapsulated iPSC-derived notochordal cells to treat intervertebral disc degeneration and low back pain |
$2,020,166 |
| Lundquist Institute for Biomedical Innovation at Harbor – UCLA Medical Center | Dr. Michelina Iacovino PhD | A Novel Therapy for Sanfilippo B |
$2,297,884 |
| University of California, Berkeley | 5106433559 Kevin E. Healy | Novel Lipid Nanoparticles for Enhancing eNOS Synthesis for Cardioprotection Post Myocardial Infarction |
$2,060,248 |
| BrainXell Therapeutics | Matthew Goodus | Autologous stem cell-derived interneuron cell therapy for spinal cord injury (SCI) |
$2,025,000 |
| University of California, San Diego | Professor Alysson R Muotri | A treatment for Rett syndrome using glial-restricted neural progenitor cells |
$1,402,240 |
| Gladstone Institutes, J. David | Dr. Deepak Srivastava | Modified RNA-Based Gene Therapy for Cardiac Regeneration Through Cardiomyocyte Proliferation |
$1,565,784 |
| The Scintillon Institute | Brian Lawson | An hematopoietic stem-cell-based approach to treat HIV employing CAR T cells and anti-HIV broadly neutralizing antibodies. |
$1,143,600 |
| University of California, Irvine | Dr. Michael Demetriou | CAR T cells targeting abnormal N-glycans for the treatment of refractory/metastatic solid cancers |
$1,414,800 |
| University of California, Los Angeles | Dr. Lili Yang | Combating Ovarian Cancer Using Stem Cell-Engineered Off-The-Shelf CAR-iNKT Cells |
$1,404,000 |
| Minutia, Inc. | Katy Digovich | Bioengineering human stem cell-derived beta cell organoids to monitor cell health in real time and improve therapeutic outcomes in patients |
$1,198,550 |
| Nanotools Bioscience | Dr. Alex Savtchenko PhD | Enabling non-genetic activity-driven maturation of iPSC-derived neurons |
$675,000 |
| University of California, Los Angeles | Dr. Xian-Jie Yang | Developing gene therapy for dominant optic atrophy using human pluripotent stem cell-derived retinal organoid disease models |
$1,345,691 |
| University of California, San Diego | Dr. Joseph G. Gleeson | Novel antisense therapy to treat genetic forms of neurodevelopmental disease. |
$1,180,654 |
| Scripps Research Institute | Stuart A Lipton | Drug Development of Inhibitors of Inflammation Using Human iPSC-Derived Microglia (hiMG) |
$1,658,123 |
| University of California, Los Angeles | Dr Dinesh S Rao | Novel methods to eliminate cancer stem cells |
$1,384,347 |
| University of California, San Diego | Dr. Michael Karin | Targeting pancreatic cancer stem cells with DDR1 antibodies. |
$1,425,600 |
| Cedars-Sinai Medical Center | Dr. Robert Barrett | A new precision medicine based iPSC-derived model to study personalized intestinal fibrosis treatments in pediatric patients with Crohn’s disease |
$776,340 |
| Scripps Research Institute | Dr Michael J Bollong | Therapeutics to overcome the differentiation roadblock in Myelodysplastic Syndrome (MDS) |
$1,244,160 |
| University of California, Davis | Dr. Kyle D Fink PhD | AAV-dCas9 Epigenetic Editing for CDKL5 Deficiency Disorder |
$1,429,378 |
| University of California, Los Angeles | Dr. Caroline Y. Kuo | Defining the Optimal Gene Therapy Approach of Human Hematopoietic Stem Cells for the Treatment of Dedicator of Cytokinesis 8 (DOCK8) Deficiency |
$1,386,232 |
| University of California, Los Angeles | Dr. Donald B. Kohn PhD | Hematopoietic Stem Cell Gene Therapy for Alpha Thalassemia |
$1,177,739 |
| Stanford University | Dr. Judith A Shizuru | Targeted Immunotherapy-Based Blood Stem Cell Transplantation |
$1,341,910 |
| Tenaya Therapeutics, Inc. | Karl N Doerner | Cardiac Reprogramming Gene Therapy for Post-Myocardial Infarction Heart Failure |
$1,017,000 |
| Intact Therapeutics, Inc. | Jeffrey Linhardt | Modulation of oral epithelium stem cells by RSpo1 for the prevention and treatment of oral mucositis |
$942,050 |
| Cytonus Therapeutics, Inc. | Dr. Edward Filardo | Development of a novel stem-cell based carrier for intravenous delivery of oncolytic viruses |
$899,342 |
| Salk Institute for Biological Studies | Ronald Mark Evans | Extending Immune-Evasive Human Islet-Like Organoids (HILOs) Survival and Function as a Cure for T1D |
$1,523,285 |
| Stanford University | Ansuman Satpathy | Preclinical development of an exhaustion-resistant CAR-T stem cell for cancer immunotherapy |
$1,420,200 |
| Stanford University | Dr. Bertha Chen | iPSC-derived smooth muscle cell progenitor conditioned medium for treatment of pelvic organ prolapse |
$1,420,200 |
| University of California, San Francisco | Brian Feeley | Matrix Assisted Cell Transplantation of Promyogenic Fibroadipogenic Progenitor (FAP) Stem Cells |
$1,179,478 |
| University of California, Los Angeles | Prof. Song Li | iPSC Extracellular Vesicles for Diabetes Therapy |
$1,354,928 |
| Scripps Health | Dr. Darryl D. D’Lima | Meniscal Repair and Regeneration |
$1,361,775 |
| The Stone Research Foundation for Sports Medicine and Arthritis | Dr. Kevin Stone | A Novel Therapy for Articular Cartilage Autologous Cellular Repair by Paste Grafting |
$1,180,309 |
| University of California, San Diego | Gene Wei-Ming Yeo | RNA-directed therapy for Huntington’s disease |
$1,253,110 |
| University of California, Irvine | Dr. Mathew Mark Blurton-Jones | Transplantation of genetically corrected iPSC-microglia for the treatment of Sanfilippo Syndrome (MPSIIIA) |
$1,083,379 |
| University of California, San Francisco | Dr. Julie Deane Saba | Providing a cure for sphingosine phosphate lyase insufficiency syndrome (SPLIS) through adeno-associated viral mediated SGPL1 gene therapy |
$1,463,400 |
| Scripps Research Institute | Luke L Lairson | Improving the efficacy and tolerability of clinically validated remyelination-inducing molecules using developable combinations of approved drugs |
$1,554,126 |
| University of California, San Francisco | Dr Julia Carnevale | Generating deeper and more durable BCMA CAR T cell responses in Multiple Myeloma through non-viral knockin/knockout multiplexed genome engineering |
$1,463,368 |
| Stanford University | Dr. Sarah C Heilshorn | Injectable, autologous iPSC-based therapy for spinal cord injury |
$789,000 |
| Navega Therapeutics | Ana Maria Moreno | Optimization of a gene therapy for inherited erythromelalgia in iPSC-derived neurons |
$1,157,313 |
| Cedars-Sinai Medical Center | Dr Eduardo Marban | New noncoding RNA chemical entity for heart failure with preserved ejection fraction. |
$1,397,412 |
| Stanford University | Dr. Stanley Qi | A novel hybrid CRISPR tool for gene network perturbation and hiPSC engineering |
$704,661 |
| University of California, San Diego | Ziwei Huang | Development of a new therapeutic for directing target specific stem cell migration and treatment |
$1,129,512 |
| University of California, San Diego | Dan S Kaufman | Human iPSC-derived chimeric antigen receptor expressing macrophages for improved cancer treatment. |
$1,256,332 |
| Stanford University | Dr. Marius Wernig MD, PhD | A universally applicable skin sheet for Dystrophic Epidermolysis Bullosa via next-generation gene editing, iPS cell technology and tissue engineering |
$1,229,040 |
| University of California, Davis | Dr. David J Segal PhD | AAV9-Cas13 gene therapy for Angelman syndrome |
$1,364,903 |
| Stanford University | Dr. Phillip C Yang | Hypoxia-specific Production of Exosomes from iPSC-derivatives for Myocardial Repair |
$1,418,023 |
| Stanford University | Kathleen M Sakamoto | Small Molecules to inhibit Nemo-like Kinase for Treatment of Diamond Blackfan Anemia |
$847,923 |
| University of California, Irvine | Munjal M Acharya | Stem cell-derived extracellular vesicles to reverse radiation-induced brain injury |
$1,064,724 |
| University of California, San Francisco | Dr Marisa Medina | iPSCs as a screening tool to predict risk of nonalcoholic fatty liver disease |
$813,000 |
| University of California, San Diego | Dr. Tannishtha Reya | Targeting Critical Regulators of Cancer Stem Cells |
$1,148,264 |
| University of California, Davis | Dr. Deborah K Lieu | Building a hiPSC-based biopacemaker |
$1,260,827 |
| City of Hope, Beckman Research Institute | Professor Yanhong Shi | Combating COVID-19 using human PSC-derived NK cells |
$249,998 |
| University of California, San Diego | Tariq M Rana | Development of COVID-19 Antiviral Therapy Using Human iPSC-Derived Lung Organoids |
$250,000 |
| University of California, Los Angeles | Dr. Thomas Carmichael M.D., Ph.D. | Human-induced pluripotent stem cell-derived glial enriched progenitors to treat white matter stroke and vascular dementia. |
$250,000 |
| University of California, Irvine | Robert F. Hunt | Optimization of a human interneuron cell therapy for traumatic brain injury |
$240,000 |
| University of Southern California | Dr. Justin K Ichida | Development of a SYF2 antisense oligonucleotide (ASO) treatment for ALS |
$222,300 |
| University of California, Irvine | Dr. Mathew Mark Blurton-Jones | Transplantation of Pluripotent Stem Cell Derived Microglia for the Treatment of Adult-onset Leukoencephalopathy (HDLS/ALSP) |
$214,668 |
| Vitabolus, Inc. | Aline Betancourt | The First Orally Delivered Cell Therapy for the Treatment of Inflammatory Bowel Disease |
$249,000 |
| Lundquist Institute for Biomedical Innovation at Harbor – UCLA Medical Center | Dr Eiji Yoshihara PhD | Dual angiogenic and immunomodulating nanotechnology for subcutaneous stem cell derived islet transplantation for the treatment of diabetes |
$250,000 |
| University of California, Los Angeles | Dr. Donald B. Kohn PhD | Hematopoietic Stem Cell Gene Therapy for X-linked Agammaglobulinemia |
$219,230 |
| University of California, San Diego | Dan S Kaufman | Human iPSC-derived chimeric antigen receptor-expressing macrophages for cancer treatment |
$222,200 |
| Stanford University | Alan G Cheng | Modulation of the Wnt pathway to restore inner ear function |
$1,389,416 |
| University of California, San Diego | Prof James S Hagood | Mesenchymal stem cell extracellular vesicles as therapy for pulmonary fibrosis |
$0 |
| University of Southern California | Dr. Neil Segil | A screen for drugs to protect against chemotherapy-induced hearing loss, using sensory hair cells derived by direct lineage reprogramming from hiPSCs |
$741,574 |
| Salk Institute for Biological Studies | Ronald Mark Evans | Therapeutic immune tolerant human islet-like organoids (HILOs) for Type 1 Diabetes |
$1,637,209 |
| Gladstone Institutes, J. David | Li Gan | Develop iPSC-derived microglia to treat progranulin-deficient Frontotemporal Dementia |
$1,547,157 |
| University of California, Los Angeles | Dr. Lili Yang | Preclinical Development of An HSC-Engineered Off-The-Shelf iNKT Cell Therapy for Cancer |
$1,404,000 |
| University of California, San Diego | Dr. Eric D. Adler MD | Genetically Modified Hematopoietic Stem Cells for the Treatment of Danon Disease |
$1,393,200 |
| Stanford University | Dr. Katja Weinacht | Regenerative Thymic Tissues as Curative Cell Therapy for Patients with 22q11 Deletion Syndrome |
$1,251,720 |
| City of Hope, Beckman Research Institute | Dr Saul J Priceman | Chimeric Antigen Receptor-Engineered Stem/Memory T Cells for the Treatment of Recurrent Ovarian Cancer |
$1,351,174 |
| Stanford University | Dr. Philip Arden Beachy PhD | Pluripotent stem cell-derived bladder epithelial progenitors for definitive cell replacement therapy of bladder cancer |
$1,265,436 |
| Scripps Research Institute | Stuart A Lipton | Drug Development for Autism Spectrum Disorder Using Human Patient iPSCs |
$1,827,576 |
| University of California, San Francisco | Dr. Hideho Okada | Non-viral reprogramming of the endogenous TCRα locus to direct stem memory T cells against shared neoantigens in malignant gliomas |
$900,000 |
| Children’s Hospital of Los Angeles | Dr. Mark R Frey | Universal Pluripotent Liver Failure Therapy (UPLiFT) |
$1,297,512 |
| University of California, San Diego | Dr. Jonathan H Lin | Small Molecule Proteostasis Regulators to Treat Photoreceptor Diseases |
$1,153,937 |
| University of California, Irvine | Dr. Aileen J Anderson | Generation and in vitro profiling of neural stem cell lines to predict in vivo efficacy for chronic cervical spinal cord injury. |
$1,575,613 |
| University of California, San Francisco | Dr. Shuvo Roy | Silicon Nanopore Membrane encapsulated enriched-Beta Clusters for Type 1 Diabetes treatment |
$1,113,000 |
| University of California, Los Angeles | Dr. Scott G Kitchen | Engineering Lifelong Cellular Immunity to HIV |
$1,701,178 |
| University of California, San Diego | Dr. Tannishtha Reya | Targeting Cancer Stem Cells in Hematologic Malignancies |
$1,960,560 |
| University of California, Los Angeles | Dr. Thomas Carmichael M.D., Ph.D. | iPS Glial Therapy for White Matter Stroke and Vascular Dementia |
$2,086,130 |
| University of California, Los Angeles | Dr. April Pyle Ph.D. | Identification and Generation of Long Term Repopulating Human Muscle Stem Cells from Human Pluripotent Stem Cells |
$2,148,519 |
| Stanford University | Dr. Kyle M Loh | Towards hepatocyte cell replacement therapy: developing a renewable source of human hepatocytes from pluripotent stem cells |
$1,968,456 |
| University of California, San Diego | Mark H Tuszynski | Neural Stem Cell Relays for Severe Spinal Cord Injury |
$1,638,900 |
| Stanford University | Dr. Helen M Blau | Stimulating endogenous muscle stem cells to counter muscle atrophy |
$2,198,687 |
| ViaCyte, Inc. | Dr. Alan D. Agulnick | Preclinical development of an immune evasive islet cell replacement therapy for type 1 diabetes |
$1,470,987 |
| University of California, San Diego | Dr Yang Xu | Development of immune invisible beta cells as a cell therapy for type 1 diabetes through genetic modification of hESCs |
$1,924,791 |
| Neurona Therapeutics | Dr. Cory R Nicholas | Development of a Cellular Therapeutic for Treatment of Epilepsy |
$1,616,536 |
| City of Hope, Beckman Research Institute | Dr. Saswati Chatterjee | Genome Editing of Sinusoidal Endothelial Stem Cells for Permanent Correction of Hemophilia A |
$2,182,193 |
| University of California, Irvine | Dr. Brian J. Cummings | Identification and characterization of the optimal human neural stem cell line (hNSC) for the treatment of traumatic brain injury (TBI) 2.0. |
$1,671,213 |
| University of California, Los Angeles | Dr. Vaithilingaraja Arumugaswami PhD | Immunization strategies to prevent Zika viral congenital eye and brain disease |
$2,128,867 |
| Rumi Scientific CA | Ali H. Brivanlou | Discovery of therapeutics for Huntington’s Disease |
$1,399,800 |
| University of California, Los Angeles | UCLA Gay M Crooks | Platform Technology for Pluripotent Stem Cell-Derived T cell Immunotherapy |
$965,636 |
| X-Therma Inc. | Dr. Xiaoxi Wei | Non-Toxic, Highly-Effective Bioinspired Cryoprotectants for On-Demand Stem Cell Therapies |
$887,883 |
| University of California, Los Angeles | Dr. Caroline Y. Kuo | Targeted Gene Editing in the Treatment of X-Linked Hyper-IgM Syndrome |
$1,512,333 |
| University of California, Davis | Dr. Deborah K Lieu | Microenvironment for hiPSC-derived pacemaking cardiomyocytes |
$2,042,438 |
| Stanford University | Dr. Mark Mercola | Multipotent Cardiovascular Progenitor Regeneration of the Myocardium after MI |
$1,809,234 |
| University of California, San Diego | Professor Yuan Chen | A Novel Approach to Eradicate Cancer Stem Cells |
$279,977 |
| City of Hope, Beckman Research Institute | Professor Yuan Chen | A Novel Approach to Eradicate Cancer Stem Cells |
$1,539,935 |
| University of California, Berkeley | 5106433559 Kevin E. Healy | Human Cardiac Chip for Assessment of Proarrhythmic Risk |
$899,581 |
| University of California, San Francisco | Dr. Holger F Willenbring | Preclinical development of AAV vector-mediated in vivo hepatic reprogramming of myofibroblasts as a therapy for liver fibrosis |
$1,638,389 |
| Scaled Biolabs Inc. | Dr Justin Cooper-White | A tool for rapid development of clinical-grade protocols for dopaminergic neuronal differentiation of Parkinson’s Disease patient-derived iPSCs |
$657,528 |
| City of Hope, Beckman Research Institute | Markus Müschen | Lgr5-mediated self-renewal in B cell selection and leukemia-initiation |
$2,183,223 |
| University of California, San Diego | Professor Alysson R Muotri | A treatment for Zika virus infection and neuroprotection efficacy |
$1,924,524 |
| Stanford University | Dr. Matthew H Porteus | Genome Editing to Correct Cystic Fibrosis Mutations in Airway Stem Cells |
$1,968,456 |
| University of California, San Francisco | Dr. Julie B Sneddon | Designing a cellular niche for transplantation of human embryonic stem cell-derived beta cells |
$2,006,076 |
| University of California, Los Angeles | Dr. John P Chute | Protein tyrosine phosphatase – sigma inhibitors for hematopoietic regeneration |
$2,115,735 |
| University of California, San Diego | Dan S Kaufman | Targeted off-the-shelf immunotherapy to treat refractory cancers |
$1,936,936 |
| Parkinson’s Institute | Dr. Birgitt Schuele | CRISPR/dCas9 mutant targeting SNCA promoter for downregulation of alpha-synuclein expression as a novel therapeutic approach for Parkinson’s disease |
$1,288,415 |
| Gladstone Institutes, J. David | Dr. Deepak Srivastava | Direct Cardiac Reprogramming for Regenerative Medicine |
$2,392,157 |
| University of California, Irvine | Leslie M Thompson | hNSC-mediated delivery of ApiCCT1 as a candidate therapeutic for Huntington’s disease |
$1,650,263 |
| Stanford University | Dr. Roel Nusse | Preclinical development of human hepatocyte progenitor cells for cell therapy |
$1,651,211 |
| University of California, San Francisco | Dr. Tejal Ashwin Desai | Thin Film Encapsulation Devices for Human Stem Cell derived Insulin Producing Cells |
$1,092,063 |
| Stanford University | Dr. Rosa Bacchetta | GENE EDITING FOR FOXP3 IN HUMAN HSC |
$984,228 |
| California Institute of Technology | Dr. David Baltimore PhD | Immunotherapy for HIV infection using engineered hematopoietic stem/progenitor cells |
$1,569,193 |
| Gladstone Institutes, J. David | Dr. Deepak Srivastava | Use of Human iPSC-derived Endothelial Cells for Calcific Aortic Valve Disease Therapeutics |
$2,400,048 |
| Scripps Research Institute | Dr. Jeanne F Loring | Autologous cell therapy for Parkinson’s disease using iPSC-derived DA neurons |
$2,299,786 |
| University of California, Davis | Dr. David J Segal PhD | MSC delivery of an artificial transcription factor to the brain as a treatment for Angelman Syndrome |
$1,055,319 |
| University of California, Berkeley | Dr. David V. Schaffer | Scalable, Defined Production of Oligodendrocyte Precursor Cells to Treat Neural Disease and Injury |
$1,627,099 |
| Stanford University | Professor Hiromitsu Nakauchi | Novel Rejuvenated T Cell Immunotherapy for Lung Cancer |
$1,968,456 |
| University of California, Los Angeles | Dr. April Pyle Ph.D. | CRISPR/Cas9 nanoparticle enabled therapy for Duchenne Muscular Dystrophy in muscle stem cells |
$2,150,400 |
